Protagonist Therapeutics, Inc
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) is an integrated drug discovery and development company focused on peptide-based medicines for inflammatory and immune-mediated diseases, blood disorders, and metabolic diseases. Its candidates include Icotyde, an oral IL-23 receptor antagonist licensed to Johnson &… From the company’s description.
Over the twelve months to Sep 30, 2026, Protagonist Therapeutics, Inc reported revenue of $551.69M, up 163.7% from a year earlier, and net income of $342.26M. Its operating margin was 58.6%, and operations generated $109.91M in cash. In fiscal 2025, it reported revenue of $46.02M, down 89.4% from fiscal 2024, and a net loss of $130.15M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Protagonist Therapeutics, Inc does
In the company’s own words
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) is an integrated drug discovery and development company focused on peptide-based medicines for inflammatory and immune-mediated diseases, blood disorders, and metabolic diseases. Its candidates include Icotyde, an oral IL-23 receptor antagonist licensed to Johnson & Johnson and under review for psoriasis; rusfertide, an injectable hepcidin mimetic developed with Takeda for polycythemia vera; and wholly owned candidates for IL-17-mediated disease, obesity, and polycythemia vera. Its discovery platform combines peptide design and medicinal chemistry to develop drug candidates, including orally delivered peptides and small molecules. The company’s programs are organized around inflammation and immunology, hematology, and obesity and metabolic disease; it does not report revenue by business segment. Development and commercialization responsibilities are shared with partners for Icotyde and rusfertide, while Protagonist advances its other candidates. At December 31, 2025, it held approximately $646 million in cash, cash equivalents, and marketable securities. Its website is https://www.protagonist-inc.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEWARK, CA
- Fiscal year end
- December
- CIK
- 1377121
- SIC
- 2834
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Protagonist Therapeutics, Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Protagonist Therapeutics, Inc · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Protagonist Therapeutics, Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Protagonist Therapeutics, Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Protagonist Therapeutics, Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Protagonist Therapeutics, Inc's last four quarterly filings that the numbers alone won't show?”